Fig. 2
NIR-II activated BPSP impaired the growth of Hepa1-6 cells effectively with the antiangiogenic ability and specific targeting ability. a Blood vessels were labeled by CD31 immunofluorescence staining in subcutaneous tumors. b, c Inverted fluorescence microscope (IFM) images and FCM analysis of cellular uptake at different times. d Ex vivo imaging of free IR780, BPI, and BPIP in Hepa1-6 tumor-bearing mice at predetermined times. The tumor was marked with a red circle. e The representative images of major organs and tumors in Hepa1-6 tumor-bearing mice were observed 24 h after administration. f Total radiant efficiency in major organs and tumors. g, h Infrared thermal imaging and temperature profile of different concentrations under 1064 nm laser irradiation (0.8 W/cm2, 5 min). i Hsp70 expression in Hepa1-6 cells based on western blotting. j The expression level of Hsp70 detected by immunofluorescence staining in Hepa1-6 subcutaneous tumors treated with different groups. k Cell viability of Hepa1-6 cells in BP@PEG + L (0.8 W/cm2, 3 min) and BP@PEG groups. l Cell viability of Hepa1-6 cells in Free SF, BPS, BPS + L, BPSP, and BPSP + L group. Data represented mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, respectively